Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
CytoSorbents Corp Market Cap
Based on ratings from 2 stock analysts, the CytoSorbents Corp stock price is expected to increase by 415.46% in 12 months. This is calculated by using the average 12-month stock price forecast for CytoSorbents Corp. The lowest target is $1 and the highest is $10. Please note analyst price targets are not guaranteed and could be missed completely.
About 2 Wall Street analysts have assignedCTSO 1 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect CytoSorbents Corp to hold. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CTSO. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CTSO.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jason Kolbert D. Boral Capital | Buy | $10 | Maintains | Nov 12, 2024 |
| Sean Lee HC Wainwright & Co. | Neutral | $1 | Reiterates | Nov 11, 2024 |
| Jason Kolbert EF Hutton | Buy | $10 | Maintains | Nov 8, 2024 |
| Jason Kolbert EF Hutton | Buy | $10 | Maintains | Nov 4, 2024 |
| Jason Kolbert EF Hutton | Buy | $10 | Maintains | Oct 22, 2024 |
| Jason Kolbert EF Hutton | Buy | $10 | Maintains | Oct 1, 2024 |
| Jason Kolbert EF Hutton | Buy | $10 | Maintains | Aug 14, 2024 |
| Sean Lee HC Wainwright & Co. | Neutral | $1 | Reiterates | Aug 14, 2024 |
| Jason Kolbert EF Hutton | Buy | $10 | Initiates | Jul 29, 2024 |
| Yuan Zhi B. Riley Securities | Buy | $3 | Reiterates | May 15, 2024 |
| Sean Lee HC Wainwright & Co. | Neutral | $1 | Reiterates | May 7, 2024 |
| Sean Lee HC Wainwright & Co. | Neutral | $1 | Reiterates | Mar 15, 2024 |
| Sean Lee HC Wainwright & Co. | Neutral | $1 | Downgrade | Dec 29, 2023 |
| Justin Walsh B. Riley Securities | Buy | $4 | Reinstates | Sep 7, 2023 |
| Sean Lee HC Wainwright & Co. | Buy | $5.5 | Reiterates | Aug 2, 2023 |
| Sean Lee HC Wainwright & Co. | Buy | $5.5 | Reiterates | May 3, 2023 |
| Sean Lee HC Wainwright & Co. | Buy | $5.5 | Reiterates | Mar 10, 2023 |
| Sean Lee HC Wainwright & Co. | Buy | $5.5 | Maintains | Nov 4, 2022 |
| Justin Walsh B. Riley Securities | Buy | $6 | Maintains | May 4, 2022 |
| Sean Lee HC Wainwright & Co. | Buy | $9 | Maintains | May 4, 2022 |
When did it IPO
2014
Staff Count
186
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Dr. Phillip P. Chan M.D., Ph.D.
Market Cap
$53.0M
In 2023, CTSO generated $31.1M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that CTSO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 11 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CytoSorbents Corporation and Converge Biotech have formed a strategic collaboration to expand their market presence in India's sepsis and critical care sectors.
Why It Matters - The collaboration between CytoSorbents and Converge Biotech enhances market potential in India's critical care sector, potentially boosting revenues and market share for both companies.
Sat, 09 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Cytosorbents Corporation (NASDAQ: CTSO) will hold its Q3 2024 earnings conference call on November 7, 2024, at 4:30 PM ET with key executives participating.
Why It Matters - Cytosorbents' Q3 2024 earnings call will provide insights into financial performance and strategic direction, influencing stock valuation and investor sentiment.
Tue, 01 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CytoSorbents has filed for FDA De Novo marketing approval for DrugSorb-ATR, aimed at reducing CABG-related bleeding linked to the blood thinner ticagrelor.
Why It Matters - FDA approval of DrugSorb-ATR could enhance CytoSorbents' market position and revenue potential, impacting stock performance and investor confidence in the company's growth prospects.
Tue, 27 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CytoSorbents Corporation (NASDAQ: CTSO) will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024, in New York.
Why It Matters - CytoSorbents' CEO and CFO presenting at a major investment conference signals potential growth opportunities and heightened investor interest, impacting stock performance and market perception.
Fri, 16 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - CytoSorbents Corporation granted inducement equity awards to new CFO Peter J. Mariani on August 14, 2024, enhancing its leadership in blood purification technology.
Why It Matters - The appointment of a new CFO and issuance of equity awards can signal strategic shifts and confidence in leadership, impacting investor sentiment and potential stock performance.
Tue, 13 Aug 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Cytosorbents Corporation (CTSO) will hold its Q2 2024 earnings conference call on August 13, 2024, at 4:30 PM ET, featuring key executives and analysts from major firms.
Why It Matters - Cytosorbents' Q2 2024 earnings call will provide insights on financial performance, strategic direction, and market trends, influencing stock valuation and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
